Table 7 Determination of dose reduction Index (DRI) for drug combo.

From: In vitro and in vivo anti-colorectal cancer effect of the newly synthesized sericin/propolis/fluorouracil nanoplatform through modulation of PI3K/AKT/mTOR pathway

Combination trial

Dose SE

Dose PRO

Dose FLU

DRI SE

DRI PRO

DRI FLU

SE + PRO

1747.9

2518.12

ND

1.22869

1.7700

ND

SE + FLU

1747.9

ND

25.854

8.4225

ND

1.2458

PRO + FLU

ND

2518.12

25.854

ND

11.1438

1.14419

nSE/PRO/FLU

1747.9

2518.12

25.8548

9.78780

14.1004

1.44776

  1. ND: not detected.